Serum levels of sCD36 and cardiometabolic variables in two Peruvian towns: Carhuamayo (4100 masl) and Mala (30 masl)
DOI:
https://doi.org/10.24265/horizmed.2017.v17n3.03Keywords:
sCD36, Cardiometabolic risk factor, Obesity, AltitudeAbstract
Objectives: To determine the serum levels of sCD36, a lipid metabolism-related molecule, in high-altitude and sea-level populations, and to establish the association of this parameter with cardiometabolic risk factors. Materials and methods: The study population consisted of 45 people from Carhuamayo (4100 masl) and 40 people from Mala (30 masl). Weight, height and blood pressure were measured. Hemoglobin was determined in whole blood, and glucose, lipid profile and sCD36 in serum. Results: It has been found that hemoglobin levels in the population of Carhuamayo were significantly higher, while weight, BMI and glucose level were significantly lower than those in the population of Mala. There was no significant difference between serum levels of sCD36 in both populations. A significant difference was observed between sCD36 mean serum levels of both populations based on the BMI, and a significant positive correlation between sCD36 and the weight and BMI. Conclusions: The observed sCD36 serum level is not related to the altitude and can be considered as a potential marker of metabolic syndrome.
Downloads
References
Febbraio M, Hajjar D, Silverstein R. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785-90
Silverstein R. Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med. 2009; 76 (Suppl 2): S27–S30.
Hoosdally S, Andress E, Wooding C, Marin C, Linton K. The human scavenger receptor CD36; glycosylation status and its role in trafficking and function. J Biol Chem. 2009; 284(24):16277–88.
Abumrad N, El-Maghrabi M, Amri E, Lopez E, Grimaldi P. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem.1993; 268(24): 17665–8.
Thorne R, Mhaidat N, Ralston K, Burns G. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 2007; 581(6):1227–32
Susztak K, Ciccone E, McCue P, Sharma K, Bottinger E. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005; 2(2): e45.
Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74.
Endeman G, Stanton L, Madden K, Bryant C, White R, Protter A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268(16): 11811–6
Podrez E, Schmitt D, Hoff H, Hazen S. Myeloperoxidase generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999; 103(11):1547–60
Jiang Y, Wang M, Huang K, Zhang Z, Shao N, Zhang Y, et al. Oxidized low density lipoprotein induces secretion of interleukin1b by macrophages via reactive oxygen species dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun. 2012; 425(2):121–6.
Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low density lipoprotein scavenger receptor CD36 in plasma, a novel marker for insulin resistance. Circulation. 2006; 114(11):1169–76.
Fernandez-Real JM, Handberg A, Ortega F, Hojlund K, Vendrell J, Ricart W. Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem. 2009; 20(6): 477–84.
Ramos-Arellano L, Muñoz-Valle J, De la Cruz-Mosso U, Salgado-Bernabe A, Castro-Alarcon N, Parra-Rojas I. Circulating CD36 and ox-LDL levels are associated with cardiovascular risk factors in young subjects. BMC Cardiovasc Disord. 2014; 14(1): 54
Handberg K, Hojlund A, Gastaldelli A, Flyvbjerg A, Dekker J, Petrie J, et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med. 2012, 271(3): 294–304
Handberg A, Skjelland M, Michelsen A, Sagen E, Krohg-Sorensen K, Russell D, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008; 39(11): 3092–5.
Park Y. Cd36, a scavenger receptor implicated in atherosclerosis. Experimental & molecular medicine. 2014;46(6):e99
Lam M, Tan K, Lam K. Glycoxidized lowdensity lipoprotein regulates the expression of scavenger receptors in THP1 macrophages. Atherosclerosis. 2004; 177(2): 313–20
Younis N, Soran H, Sharma R, Charlton-Menys V, Durrington P. Lipoprotein glycation and atherogenesis. Clin Lipidol. 2009; 4(6):781–90
Sampson M, Davies I, Braschi S, Ivory K, Hughes D. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Atherosclerosis. 2003; 167(1): 129–34
Furuhashi M, Ura N, Nakata T, Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care. 2003; 26(2): 471–4
Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med. 2001; 7(7): 840–846
Bonen A, Tandon N, Glatz J, Luiken J, Heigenhauser G. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes. 2006; 30(6): 877–83
Liang C, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall A. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest. 2004; 113(5): 764–73
Segura-Vega L, Regulo-Agusti C, Ramírez J. Factores de Riesgo de las Enfermedades Cardiovasculares en el Perú. Estudio TORNASOL. Rev peru cardiol. 2006; 32:82-128
West J, Schoene R, Luks A, Milledge J. High Altitude Medicine and Physiology. 5nd ed. CRC Press, Taylor & Francis Group Boca Raton; 2013
National Cholesterol Education Program (NCEP). Third Report of the National CholesterolEducation Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol In Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421
Mohanna S, Baracco R, Seclen S. Lipid profile, waist circumference, and body mass index in a high altitude population. High Alt Med Biol. 2006; 7(3):245-55.
Gonzáles G, Tapía V. Asociación de los diferentes niveles de hipoxemia en la altura con el perfil lipídico y la glucemia en varones y mujeres a 4,100 m de altitud en los Andes Centrales del Perú. Endocrinol Nutr. 2012; 60(2):79-86.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
